OICHARTS
8 AMThe 8 AM report →
PharmaMedium impactAfter close

Natco Pharma gains approval for generic semaglutide

after close1 source ↓written by the desknot a recommendation

Natco Pharma received regulatory approval for its generic semaglutide, targeting the growing diabetes and obesity market in India. This approval coincides with ongoing patent litigation against Novo Nordisk, whose patent for semaglutide expires in March 2026. The outcome of this legal battle will significantly impact Natco's market entry strategy.

Not investment advice. For informational purposes only.

OI Charts is not a SEBI-registered investment adviser or research analyst. This bulletin was written by the OI Charts desk from the public sources listed here. It is commentary on market conditions, not a basis for any investment decision and not a recommendation to buy or sell any security. Prices as of 14 Feb 2026, 16:07 IST.

Sourcesnews.google.com

Read inENहिंతెमराதગુ

The market after the news

NATCOPHARM closed +7.0% on the day of the news, from ₹823.85 to ₹881.45; Nifty +0.8% over the same session.

Bulletin at 16:07 IST on 14 Feb 2026. Every change is measured from ₹823.85, the last close before it, on 13 Feb. Nifty 50 is measured over the same sessions.

  • NATCOPHARM close ₹
  • Nifty 50, rebased to the close before the news
  • close before the news
  • above it
  • below it
NATCOPHARM closes around the bulletin against the close before the news, with Nifty 50 rebased to it737.51863.01988.50axis spans 34%before the news · 13 Feb823.85Nifty 50NATCOPHARMbulletinD0+1+3+59 Feb19 Feb2 MarReference close ₹823.85. 16 sessions from 9 Feb to 2 Mar; the price axis spans 34 percent.
price axis fixed at 4 × the 14-session true range around the close before the news · values printed at each marked session
Closes after the news against the close before it, with Nifty 50 over the same span
SessionClose ₹Change %Nifty %
Before13 Feb₹823.85basebase
On the day16 Feb₹881.45▲ +7.0%▲ +0.8%+6.2 pp difference
+1 session17 Feb₹884.70▲ +7.4%▲ +1.0%+6.4 pp difference
+3 sessions19 Feb₹888.30▲ +7.8%▼ −0.1%+7.9 pp difference
+5 sessions23 Feb₹893.00▲ +8.4%▲ +0.9%+7.4 pp difference
Gap at the open, % · ₹
▲ +0.8%+6.59 on 16 Feb
Day's range, % · ₹
13%≈ 100 high to low
Volume on the day
45.12×the 20-session average
Futures OI on the day
—
Futures OI open, lots
—
Futures premium, ₹
—
Puts per call, by OI
—
Max pain
—

Source NSE UDiFF bhavcopy · NATCOPHARM on the desk →

Thread · NATCOPHARMAll NATCOPHARM bulletins →

Related